PF-Atlas › Clinical Trials › NCT01280994
Hyperpolarized 129Xe MRI for Imaging Pulmonary Function
Hyperpolarized 129Xenon Gas · Phase 2
Registry ID
NCT01280994
Phase
Phase 2
Status
Recruiting
Drug / intervention
Hyperpolarized 129Xenon Gas
Sponsor
Bastiaan Driehuys
Start
2011-01
Enrollment
445
Locations
1
About this trial
The purpose of this study is to develop and evaluate the usefulness of MRI using 129Xe gas for regional assessment of pulmonary function. Specifically, three forms of 129Xe MRI contrast will be the investigators focus - 1) imaging of the 129Xe ventilation distribution, 2) imaging the alveolar microstructure via the 129Xe apparent diffusion coefficient (ADC), and 3) imaging 129Xe that dissolves in the pulmonary blood and tissues upon inhalation. Such imaging of 129Xe gas transfer is expected to be uniquely sensitive to pathologies affecting gas exchange (fibrosis, emphysema, pulmonary hypertension) and provide new insights regarding the normal resting heterogeneity of pulmonary gas exchange.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT01280994 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.